throbber
J. Pcptide Re., 50, 1997. 222-230
`Printed in the Uiiitrd Srrirrs ofAinrriro
`
`1111 t r g l m reTr,r\ r d
`
`~
`
`Copwight 0 M~ink.\gaard, I9117
`JOURNAL OF PEPTIDE RESEARCH
`lSSN 13Y7-002X
`
`Synthesis, biological activity and isomerism of guanylate
`cyclase C-activating peptides guanylin and uroguanylin
`
`JOACHIM KLODT,' MICHAELA KUHN,' UTE C. MARX,' SILKE MARTIN,' PAUL ROSCH,'
`WOLF-GEORG FORSSMANN' and KNUT ADERMANN
`'Niedersachsisches Irisritutfur Peptid-Forschurig (IPF}, Hannovel; and
`Lehrstuhl fur Strukrur und Clieniie der Biopolymere, Uiiiversitat Bayreuth, Germany
`
`Received 12 February. revised 19 March. accepted for publication 10 May 1997
`
`Recently, the peptides guanylin and uroguanylin were identified as endogenous ligands of the membrane-bound
`guanylate cyclase C (GC-C) that is mainly expressed in the intestinal epithelium. In the present study, bioactive
`guanylin and uroguanylin have been prepared by solid-phase methodology using Fmoc/HBTU chemistry. The
`two disulfide bonds with relative 113 and 2/4 connectivity have been introduced selectively by air oxidation of
`thiol groups and iodine treatment of Cys(Acm) residues. Using this strategy, several sequential derivatives were
`prepared. Temperature-dependent HPLC characterization of the bioactive products revealed that guanylin-related
`peptides exist as a mixture of two compounds. The isoforms are interconverted within approximately 90 min,
`which prevents their separate characterization. This effect was not detected for uroguanylin-like peptides. Synthetic
`peptides were tested for their potential to activate GC-C in cultured human colon carcinoma cells (T84), known
`to express high levels of GC-C. The results obtained show that both disulfide bonds are necessary for GC-C
`activation. The presence of the amino-terminally neighboring residues of CyslO4 for guanylin and CyslO0 for
`uroguanylin has been found to be essential for GC-C stimulation. Unexpectedly, a hybrid peptide obtained
`from substitution of the central tripeptide AYA of guanylin by the tripeptide VNV of uroguanylin was not
`bioactive. 0 Munksgaard 1997.
`Ke! n.orcf.c: cGMP: ditulfide: guanylate cyclase C: guanylin: uroguanylin; peptide hormone: peptide synthesis;
`topological isomerism
`
`~
`
`Abbreviations: Acm, acetamidomethyl: Boc. trrt-butyloxycar-
`bonyl; cCMP, cyclic 3',5'-guanosine monophosphate: DCM.
`dichloromethane; DIEA. N,N-diisopropylerhylamine: EDT.
`ethanedithol; ESMS, electrospray mass spectrometry: Fnioc.
`fluorenylmethoxycarbonyl: GC-C, guanylate cyclase C: HBTU.
`2-( 1 H-benzotriazole- I -yl)- I . I ,3.3-tetraniethyluronium hexafluoro-
`phosphate; HOAc, acetic acid: HOBt. N-hydroxybenrotria7ole;
`Isc, short-circuit current; MeCN, acetonitrilc: NMP. N-methyl-
`pyrrolidinone; NMR, nuclear magnetic resonance: PHB. p-alkoxy-
`benzyl alcohol; TBME, tert-butylmethylether: TBTU. 2-( IH-benzo-
`triazole- 1 -yl)- I , 1,3.3-tetramethyluronium tetratluoroborate: TFA.
`trifluoroacetic acid.
`Residue numbers refer to the circulating proguanylin-(22-l IS)
`(7) and cDNA-deduced uroguanylin precursor containing I I 2
`amino acids (11) and are used throughout the text.
`Part of this work has been presented in abstract form at the 4th
`International Symposium. Solid Phase Synthesis & Comhinato-
`rial Chemical Libraries, Edinburgh. Scotland [Adennann. K.. Neitz.
`S., Marx. U., Rosch. P. & Forssmann. W.G. (1995) Abstract Pi 1.
`
`Guanylin and uroguanylin are novel mammalian pep-
`tide hormones that are ligands of intestinal receptor
`guanylate cyclase C (GC-C). GC-C activation increases
`the intracellular concentration of cyclic guanosine
`monophosphate (cGMP), which in turn modulates in-
`testinal water and electrolyte secretion (1-5). The en-
`docrine role of this new family of regulatory peptides
`with respect to epithelial ion transport and a functional
`link between intestine, kidney and other tissues are top-
`ics of current research in physiology. Guanylin, origi-
`nally isolated as a peptide of 15 residues from rat
`jejunum (6), also circulates in human plasma as a
`larger hormone containing 94 amino acids (7).
`Uroguanylin was isolated from urine and represents a
`second activator of GC-C (8, 9). Recently, an
`amino-terminally elongated form of 24 amino acid resi-
`dues was shown to represent a plasma-circulating form
`of uroguanylin (10, 11). It was also reported that
`prouroguanylin is present in plasma and urine in pa-
`tients with chronic renal failure (12).
`
`222
`
`MYLAN - EXHIBIT 1034
`
`

`

`Both guanylin and uroguanylin share a significant
`sequence homology with a specific family of bacterial
`enterotoxins (Fig. 1). In particular, Escherichia coli
`heat-stable enterotoxin STa causing secretory diarrhea
`in mammals was shown to activate GC-C with a sig-
`nificantly higher efficacy than guanylin and uroguany-
`lin (13, 14). It was predicted that the four cysteine
`residues of guanylin and uroguanylin form two disul-
`fide bonds in a connectivity that is also contained in
`E. coli STa ( I 5, 16). Synthesis of the three possible dis-
`ulfide isomers of guanylin confirmed that only one of
`the several possible disulfide isomers acts as a GC-C
`activator and therefore is able to increase the intracellu-
`lar cGMP level (2, 17). Similarly, uroguanylin with
`equivalent disulfide connectivity was shown to stimu-
`late GC-C in a concentration-dependent manner (9,lO).
`It is generally accepted that the other two disulfide iso-
`mers of uroguanylin are biologically inactive.
`Considering the molecular interaction of guanylin
`and uroguanylin with the extracellular domain of their
`receptor, the disulfide loops drastically reduce their con-
`formational flexibility, resulting in a highly con-
`strained three-dimensional structure. In this context, a
`unique feature of guanylin and uroguanylin is that both
`peptides exist in two distinct conformations. Although
`not separable by chromatographic methods, it was re-
`ported that, for synthetic guanylin-( 103-1 15) and the
`tryptic fragment (94-1 15) obtained from recombinant
`proguanylin, two isomers are present in aqueous solu-
`tion, as detected by NMR spectroscopy ( 1 8). In that
`study, it was concluded that one of the two forms adopts
`a conformation similar to that observed for E. coli
`enterotoxin STa (19). We have shown that guanylin-(99-
`1 15) also appears as a mixture of two compounds which
`are detectable by means of low-temperature HPLC (20).
`Very recently, it was reported that solid-phase synthe-
`sis of human uroguanylin-(97-l12) yields two topo-
`logical isomers which could be separated by HPLC
`(21). In another study, it was reported that only one
`of these isomers is bioactive and different native forms
`of uroguanylin have been identified using polyclonal
`antisera raised against the two conformational isomers
`of synthetic uroguanylin (1 2).
`In this communication, we describe a general strat-
`egy that allows solid-phase synthesis of guanylin/
`uroguanylin-type peptides with regic-selective introduc-
`tion of disulfide bonds. Using this tool, several deriva-
`tives of guanylin and uroguanylin have been
`
`Guanylin (99-1 15)
`Uroguanylin (97- 1 12)
`Uroguanylin (89-1 12)
`E co/i S la
`
`GC-C-activating peptides guanylin and uroguanylin
`
`synthesized to gain insight into sequential and confor-
`mational requirements for the interaction between the
`peptide regulators and their receptor.
`
`EXPERIMENTAL PROCEDURES
`Reagents for peptide synthesis. Fmoc amino acids
`(L-configuration) were purchased from Orpegen
`(Heidelberg, Germany) and PerSeptive Biosystems
`(Wiesbaden, Germany). Protective groups were:
`Arg(Pbf), Asn(Trt), Asp(OtBu), Cys(Acm), Cys(Trt),
`Glu( 0 t Bu) , Ly ~(Boc), Ser( tBu), Thr( tBu) , Tyr( tB u) .
`Syntheses were carried out using TentaGel resins (Rapp
`Polymere, Tubingen, Germany). HBTU was obtained
`from Perkin-Elmer/ABI (Weiterstadt, Germany),
`TBTU was from Peboc (Llangefni, Wales). NMP was
`purchased from Merck (Darmstadt, Germany). Other
`reagents and solvents were of analytical or higher grade
`and obtained from Merck or Fluka (Neu-Ulm, Ger-
`many). E. coEi heat-stable enterotoxin STa was from
`Sigma (Deisenhofen, Germany).
`
`Solid-phase peptide synthesis. Peptide assemblies
`were carried out in NMP at a scale of 0.1 mmol using a
`preloaded Fmoc-Cys(Trt)-TentaGel S Trt or S PHB resin
`(0.23 mmol/g) for guanylin-related peptides and
`Fmoc-Leu-TentaGel S Trt (0.19 mmol/g) for uro-
`guanylin-related peptides. For the synthesis of guanylin
`peptides, CyslO4 and Cysl12 were Acm-protected,
`whereas CyslO7 and C y s l l 5 were Trt-protected.
`Uroguanylin was synthesized with Trt protection for cys-
`teines in positions 103 and 111, and Acm protection
`at CyslOO and Cysl08. As a standard procedure, all
`peptides were synthesized on a 433A peptide synthe-
`sizer (Perkin-Elmer/ABI) with conditional conductiv-
`ity monitoring of Fmoc deprotections. In addition,
`guanylin-(99-115) and uroguanylin-(89-112) were
`synthesized manually on preloaded TentaGel S PHB
`resins (2 mmol) using double coupling cycles for each
`residue (10 mmol Fmoc amino acid, 9.5 mmol TBTU,
`4 mmol HOBt and 20 mmol DIEA). Acylations were
`performed for 2 h and monitored by ninhydrin assay
`(22). Fmoc groups were cleaved with 20% piperidine
`in NMP for 20 min. After completion of syntheses,
`resins were washed with DCM and dried under vacuum.
`For resin cleavage and deprotection, the dry peptidyl
`resins were treated at room temperature with a fresh
`mixture of TFA/EDT/H20 (94:3:3, 20 mL/g) for 1.5-
`2 h. Subsequently, the peptide-containing cleavage cock-
`tail was filtered and slowly dropped into chilled TBME
`(100 mW20 mL TFA). Precipitated crude peptides were
`separated by centrifugation, washed twice with cold
`TBME and dried under vacuum without lyophilization.
`
`FIGURE 1
`Primary structures of GC-C-activating peptides. Conserved rebi-
`dues are shaded.
`
`Disulfide formation and purification. To introduce the
`first disulfide bond by air oxidation, the crude peptide
`was dissolved in water (0.5-1 mg/mL). pH was ad-
`
`223
`
`

`

`J. Klodt et al.
`justed between 7.8 and 8.5 with diluted NH?. The so-
`lutions were stirred until no free thiol was detectable
`by Ellman's reagent (23) and C 18-HPLC monitoring.
`Mixtures were acidified with TFA (pH 2.5), loaded di-
`rectly onto a preparative C18-HPLC column and puci-
`fied (Vydac C18, Hesperia, CA, 47 x 300 mm, 300 A,
`15-20 pm, buffer A; 0.1% TFA, buffer B: 0.1% TFA
`in MeCN/water, 80:20, gradient 0-1 00% B in 60 min,
`flow 50 mL/min, UV detection at 230 nm). Fractions
`containing the pure monocyclic intermediate as de-
`tected by ESMS and C 18-HPLC were collected and
`lyophilized. Cleavage of Acm groups and introduction
`of the second disulfide bond were carried out by dis-
`solving the purified monocyclic Acm2-peptides in
`deairized HOAdO.1 M HC1 (4:1, pH 2, 1 mg/mL). A
`solution of iodine (10-20 eq, 0.05 % I ) in HOAc was
`added and after 30-60 min the excess iodine was re-
`duced by the addition of fresh 0.1 M sodium thiosul-
`fate, resulting in a colorless solution. After dilution
`with water (2 volumes), the bicyclic products were
`obtained from preparative C18-HPLC (Vydac C18, 20
`x 250 mm, 300 A, 10 pm, buffer A: 0.1% TFA; buffer
`B: 0.1 % TFA in MeCNIwater 80:20, gradient 0-100%
`B in 60 min, flow 8 mL/min, 230 nm). Purification
`was performed at 50 "C (guanylin peptides) or room
`temperature (uroguanylin peptides). In the case of in-
`sufficient purity, HPLC purification of bicyclic prod-
`ucts was repeated.
`
`Analytical methods. Analytical HPL$ was performed
`on a Vydac C I8 column (5 pm, 300 A, 4.6 x 250 mm,
`buffer A: 0.06% TFA; buffer B: 0.055% TFA in 80%
`MeCN, flow rate 0.8 mL/min, 215 nm). Tempera-
`ture-dependent HPLC characterization of purified pep-
`tides was carried out using an adjustable column oven
`with a Nucleosil C18 PPN column (2 x 250 mm, 5
`pm, 100 A, flow rate 0.2 mL/min, 215 nm, Macherey
`& Nagel, Diiren, Germany). Mass spectrometry was
`performed using a triple-stage quadrupole mass spec-
`trometer (Sciex API 111, Perkin-Elmer). Peptide
`samples were dissolved in MeCN/water (1 : 1) contain-
`ing 0.2% AcOH to a concentration of 0.1 mg/mL and
`infused into the ion spray using a syringe pump at a
`flow rate of 5 pL/min. The ion spray interface was
`set to a positive potential of 5 kV. Amino acid analy-
`sis was carried out on a Aminoquant 1090L analyzer
`(Hewlett-Packard, Waldbronn, Germany). Sequence
`analysis was performed on a 494A protein sequencer
`(Perkin-Elmer). Two-dimensional NMR spectroscopy
`(NOESY, Clean-TOCSY, DQF-COSY) was performed
`on a Bruker AMX600 spectrometer at 284 K using stan-
`dard methods (24,25). Synthetic peptides were dissolved
`in H,O/D,O (9:l) at a concentration of 5-10 mg/mL.
`
`T84 cell cGMP bioassay. Determination of the
`GC-C-stimulating activity of synthetic peptides was evalu-
`ated as described elsewhere in detail (1, 7, 10). Cultured
`
`224
`
`human colon carcinoma (T84) cells were incubated with
`synthetic peptides for 60 min in the presence of the phos-
`phodiesterase inhibitor isobutylmethylxanthine (IBMX, 1
`8
`mv, Si ma). The peptides were tested in concentrations
`of 10- to 10f' M . The given concentrations refer to
`the net peptide content specified by amino acid analy-
`sis. Effects on intracellular cGMP level were compared
`with those of E. coli enterotoxin STa. cGMP was mea-
`sured using a specific radioimmunoassay (26).
`
`lor1 transport (Ussing chamber experiments). Female
`Wistar rats maintained under standard temperature,
`light conditions and with free access to water and food
`were used. For the assessment of active electrogenic
`ion transport, specimens of proximal colon were dis-
`sected and serosal and muscular layers separated. Sheets
`of isolated mucosa were mounted in Ussint; chambers
`(27) with an exposed surface area of 1 cm' and auto-
`matically voltage-clamped as described previously (3,
`4). Short-circuit current (Isc) was recorded continu-
`ously. After an equilibrium period of 30 min, cumu-
`lative concentrations of synthetic peptides were added
`to the luminal side of the colonic mucosa.
`
`RESULTS AND DISCUSSION
`
`Synthesis
`In agreement with earlier observations (2, 21) and in
`contrast to other peptides like endothelin (28) and low
`molecular weight toxins (29), oxidative folding of
`tetrathiol-containing precursors of guanylin and
`uroguanylin did not result in bioactive products that
`increase intracellular cGMP concentration. The re-
`duced peptides had a poor solubility in aqueous buffers.
`Further attempts to synthesize guanylin with different sets
`of orthogonal side-chain protective groups for the cys-
`teine residues like acetamidomethyl (Acm), tert-butyl
`(tBu), tert-butylthio (StBu), p-methoxybenzyl (Mob)
`or allyloxycarbonylaminomethyl (Allocam) resulted in
`products that were only slightly soluble in buffers re-
`quired for disulfide formation. To improve solubility,
`guanylin was initially synthesized with additional
`amino-terminal Glu-Asp residues which do not influ-
`ence the bioactivity. Guanylin and uroguanylin were
`synthesized using Acm and Trt protection for cysteine
`residues with Cys(Trt) at the C-terminal position. De-
`tectable by conductivity monitoring, qualitative ninhy-
`drin assay or HPLCESMS of intermediates, guanylin and
`uroguanylin represent difficult peptides. Starting from
`Alal 10 (guanylin) and Val106 (uroguanylin), acylations
`and cleavage of Fmoc groups tended to proceed
`slowly. For the manual synthesis of larger amounts of
`peptides, acylations were carried out for 2 h whereas
`Fmoc peptidyl resins were treated for 20 min with pi-
`peridine. Exchanging the pairs of cysteine protective
`groups resulted in a product of slightly less purity.
`The first loop between the unprotected cysteines of
`
`

`

`all synthetic compounds was introduced by air oxida-
`tion at pH 8. The proceeding oxidation process could
`be monitored easily by Ellman's test (23), HPLC com-
`parison of thiol peptides and monocyclic products or
`ESMS analysis after iodoacetamide treatment (30) (Fig.
`2). Depending on the sequence, a period of 12-72 h
`was necessary for this step. For the subsequent work-up
`of monocyclic Acm2-peptides, it was essential to
`acidify the mixture to pH 2.5 (HCl or TFA). As de-
`tected by MS and HPLC, direct lyophilization or pu-
`
`2+
`[M+2H] 1372
`
`1
`
`[ M + H j 1848
`
`[ M + 2 H r 1300
`
`[M+H]+ 1703
`
`------
`
`5
`
`10
`
`15
`
`20
`
`25
`
`30
`
`5
`
`10
`
`IS
`
`20
`
`25
`
`30
`
`Time (min)
`
`FIGURE 2
`HPLC characterization of linear, monocyclic and purified
`peptides. ( a ) human uroguanylin-(89-112) FKTLRTIAN-
`DDCELCVNVACTGCL; ( b ) human guanylin-(99-115),
`EDPGTCEICAYAACTGC. Top traces, linear peptides after
`TFA cleavage; middle traces, monocyclic Acml-peptides;
`bottom traces, bicyclic, purified products. HPLC gradient (Vydac
`C 18): linear and monocyclic peptides, 20-70% buffer B in 30
`min at room temperature; bicyclic peptide, 10-50% buffer B in
`40 min at 40 "C. Masses given were determined by ESMS.
`
`GC-C-activating peptides guanylin and uroguanylin
`
`rification of a pH 8 solution of monocyclic peptides re-
`sulted in products with a poor solubility, possibly
`caused by further oxidation of cysteines. To obtain fi-
`nal products of a high purity, additional HPLC puri-
`fications of the monocyclic Acm2-peptides were
`performed. Cleavage of Acm groups with subsequent
`formation of the second disulfide with excess iodine
`at pH 2 (HCl) was a suitable method with suppression
`of disulfide rearrangement (3 1). The absence of HCl
`led to unsatisfactory products. Different solvents like
`mixtures of water, acetic acid and methanol did not
`affect iodine treatment. Alternative attempts at disul-
`fide formation using on-resin procedures and the
`solvent-dependent selectivity of iodine treatment of
`free thiols and Acm-protected cysteine residues failed
`(32); dimerization was a significant side effect. Over-
`all yields were between 2 and 8% because of the re-
`peated HPLC purifications of mono- and bicyclic
`peptides. With guanylin-(99-115) and uroguanylin-
`(89-1 12) as examples, Fig. 2 shows analytical HPLC
`of intermediate compounds and final products which
`were unambiguously characterized by ESMS. Using
`this general synthetic procedure, guanylin and
`uroguanylin as well as several derivatives have been
`prepared and characterized (Table 1). As recently com-
`prehensively reviewed (31,33), our results of the syn-
`thesis of guanylin and uroguanylin are another
`indication that suitable reaction conditions for each
`single peptide containing multiple disulfide bonds must
`be worked out accurately.
`Unlike other polycyclic peptides with multiple cys-
`tines within a short sequence segment, low-tempera-
`ture HPLC analysis of purified guanylin-(99-115) (4)
`showed two components in a ratio of about 1 : 1. ESMS
`analysis resulted in only one signal with the expected
`molecular weight of 1703 Da. Reverse-phase HPLC
`with a stepwise increase of column temperature led to
`one sharp absorption at high temperature. Cislrruns
`isomerism of the Asp100-Pro101 amide bond was
`excluded as the reason for this observation by
`temperature-dependent HPLC analysis of guanylin-
`(101-1 15) (3) with an amino-terminal Pro residue.
`Shown in Fig. 3, a and b, peptides 3 and 4 exhibit the
`identical HPLC characteristic at different temperatures.
`A corresponding temperature effect was observed with
`guanylin-( 104-1 15) (l), [desThrl03]guanylin-(99-
`115) (7) and compounds 12 and 13. In contrast,
`guanylin-( 103-1 15) (2) appears as a single HPLC peak.
`This is consistent with an earlier report (1 8). Our pre-
`liminary NMR experiments with guanylin-(99-115) (4)
`confirmed the presence of two distinct compounds in
`a ratio of about 1 : 1 (20). The guanylin/uroguanylin hy-
`brid 9 had a major HPLC peak, but two-dimensional
`NMR spectroscopy revealed the presence of two com-
`ponents in equivalent amounts (data not shown). As
`expected, monocyclic Cys(Acm)2 intermediates 10, 11
`and 18 were homogeneous during HPLC. A reversed in-
`
`225
`
`

`

`2938.5 I 1470.5'
`251 1.9 I 1257.0'
`2614.1 I 1372.0'
`2469.9 I 1235.0'
`2484.9 I 1242.0'
`2599.0 I I300.0'
`1667.9 I 1667.Sh
`1515.6 I 1516.0"
`1458.7 I 14S9.0h
`1845.9 I I 846.0h
`1845.9 I I 846.0h
`1709.9 I 17 I O.Oh
`1582.7 I 1582.Sh
`I6O1.8 I 1601.0h
`1573.8 I 1573.Sh
`1702.9 I 1703.Sh
`1702.9 I I 703.Sh
`1458.7 I 1459.0h
`1304.5 I 1304.Sh
`1203.4 I 1203.Sh
`
`Calc./ESMS
`Mass (Da)
`
`n.d., not determined.
`'[M+2H]".
`h[M+H]+.
`gBiotinAhx, N-(Biotinyl-6-aminocaproyl).
`'Sequence from guinea pig uroguanylin obtained by translation of the corresponding mRNA (EMBL database, Accession no. 274738).
`eMonocyclic Acmz-intermediates.
`dSequences from porcine and guinea pig guanylin obtained by translation of the corresponding mRNA (EMBL database, Accession nos. 273607 and 274736.
`'Monocyclic Acmz-intermediates.
`'Monocyclic Acm2-intermediates.
`"Reversed order of disulfide bond formation using Cys(Acm)l07/115 and Cys(Trt)l04/112.
`
`n.d.
`Ala 2.13 Arg 0.99 Val 0.96 Met 0.95 Ile 1.00 Leu 3.08 Asx 3.99 Glx 2.35 Gly 1.20 Thr 1.82
`n.d.
`Ah 2.07 Arg 0.99 Val 2.02 Phe 0.97 Ile 0.98 Lci 3.05 Asx 4.06 Cly 1.17 Thr 2.21 Lys 0.85
`Ala 2.08 Arg I .OI Val I .94 Phe 1.00 IIc 0.93 Leu 3.10 Asx 3.09 Glx 0.71 Gly 1.23 Thr 2.57 Lys 1.02
`Ala 2.12 Arg 1.04 Val 1.94 Phe 0.98 Ile 0.98 Lcu 3.05 Asx 3.95 Glx 0.71 Gly 1.1 I Thr 2.31 Lys 0.97
`Ala 1.04 Val 1.89 Leu 2.04 Asx 3.84 Glx 0.72 Gly 1.19 Thr 0.93
`Ala 3.08 Ilc 0.98 Asx 0.78 Glx 0.65 Gly I .03 Thr I .70 Tyr 0.82 Pro I .02
`Ala 4. I2 Ilc 0.93 Glx 0.63 Gly I. 15 Thr 0.78 Tyr 0.88 Pro I .04 Ser 0.45
`n.d.
`n.d.
`Ala I .OI Ile 0.97 ASX I .83 Glx I .42 Gly 2.02 Thr I .77 Pro I .02 Val I .93
`Ala 2.02 11s 0.97 Asx 0.81 Glx 1.31 Gly 4.06 Thr I .72 Pro 1.06
`Ala 3.06 Ile 0.94 Asx 0.66 Glx I. I2 Gly 2.02 Thr 0.90 Tyr 0.8 I Pro I .01
`Ala 3.22 111: 0.93 Asx 0.90 Glx 0.72 Gly I .Y8 Thr I .63 Tyr 0.79 Pro 0.98
`Ala 3.1 I Ilc 0.95 Asx 0.89 Glx 1.37 Gly 2.23 Thr 1.73 Tyr 0.86 Pro 1.12
`Ala 3.02 Ilc 0.94 Asx 0.97 Glx I .56 Gly 2.0 I Thr I .6 I Tyr 0.84 Pro I .OX
`Ala 3.31 Ile 1.00 Glx 0.63 Gly 0.09 Thr 1.56 Tyr 0.94 Pro 0.92
`Ala 3.09 Ile 0.95 Glx 0.59 Gly 1.02 Thr 1.60 Tyr 0.88
`Ala 3.06 Ilc 0.98 Glx 0.68 Gly I. 13 Thr 0.84 Tyr 0.75
`
`(Biotin Ahx)FKTLRTIANDDCELCVNVACTGCL
`LQALRTMDNDECELCVNI ACTGC
`FKTLRTIANDDC( Acm)ELCVNVAC(Acm)TGCL
`FKTLRT[ANDDCI,CVNVACTGCl,
`FKTLRTIANDCELCVNVACTGCL
`FKTLRTI ANDDCELCVNVACTGCL
`NDDCELCVNVACTGCL
`PNTCEICAYAACTGC
`PSTCEICAYAACAGC
`EDPGTCEIC(Acm)AYAACTGC( Acrn)
`EDPGTC( Acm)EICAYAAC( Acm)TGC
`EDPGTCEICVNVACTGC
`EDPGTCEIC AGGACTGC
`EDPGCEICAYA ACTGC
`EDPGTCICAYAACTGC
`EDPGTCEICAYAACTCC
`EDPGTCEICAYAACTCC
`PGTCEICAYAACTGC
`TCEICAYAACTGC
`CEICAYA ACTGC
`
`2Qg
`19'
`I 8'
`17
`I6
`15
`14
`I3
`I2d
`11'
`I Oh
`9
`8
`7
`6
`5
`4
`3
`2
`I
`
`Amino acid composition
`
`No. Sequence
`
`

`

`troduction of disulfides did not alter the low-temperature
`HPLC pattern of guanylin-(99-115) (5).
`Rechromatography of the collected peaks I and I1
`from an analytical HPLC run of guanylin 4 at 11 "C
`(Fig. 3b) unexpectedly did not result in single peaks.
`Proving the interconvertibility between the two iso-
`mers, the mixture of both compounds was recovered
`after HPLC of isolated peaks I and I1 (Fig. 3d). There-
`fore, racemization of cysteine residues during peptide
`assembly can be excluded as the reason for two HPLC
`peaks with identical molecular weights. Although our
`attempts to separate both isoforms failed, repeated
`cycles of analytical HPLC, peak collection and
`rechromatography led to concentrated peaks I and 11,
`respectively (Fig. 3d). Variation of the conditions of
`HPLC analysis of peptides 3 and 4, the HPLC (phos-
`phate buffer, pH 3) and storage of the collected
`isoforms corresponding to peaks I and I1 (Fig. 3, a
`and b) for different periods (up to 30 days) at differ-
`ent temperatures, even at +50 "C and liquid nitrogen
`temperature, did not change the original HPLC char-
`acteristics. From the results of NMR spectroscopy, the
`half-life of guanylin isomers was estimated to be at
`least in the range of seconds (18). Regarding the
`rechromatography of the collected isoforms, which was
`performed about 90 min after collection of both iso-
`mers, a maximum half-life of 90 min of the isoforms
`can be concluded. However, the mechanism of
`interconversion remains unclear. Because of a high ac-
`
`GC-C-activating peptides guanylin and uroguanylin
`
`tivation barrier for a mutual exchange of isoforms,
`which has been described to be in excess of 20 kcaV
`mol(1 8), an intermediate opening of one disulfide loop
`followed by a cystine rearrangement may be consid-
`ered as an alternative mechanism for the formation of
`topoisomers. This pathway seems to be unlikely be-
`cause the formation of positional disulfide isomers by
`the attack of a free thiol on the second disulfide would
`be a likely side effect. There are no experimental indi-
`cations for a cystine rearrangement. Recently, Chino et
`al. (21) reported the isolation of two isoforms of syn-
`thetic uroguanylin-(97-112) (14). Depending on the
`order of introduction of the disulfide bonds, the isomers
`were formed in a different ratio. Although we can con-
`firm this result, only one compound was isolated after
`synthesis of uroguanylin-(89-112) (15) and other
`uroguanylins (Fig. 3c). Our preliminary NMR studies
`of synthetic peptide 15 demonstrated that only one
`compound is present in solution (data not shown).
`However, it is possible that the second isomer was not
`noticed during chromatographic product separation.
`Our results show that guanylins 3 and 4 exist as a
`mixture of two isoforms which are interconverted. As
`suggested for uroguanylin (21), the order of introduc-
`tion of the two disulfide loops had no influence on the
`product composition. This was revealed by synthetic
`peptides 4 and 5 which showed an identical HPLC pat-
`tern. An amino-terminal truncation of the first two resi-
`dues of guanylin in peptide 2 only influences the
`
`I
`
`11°C Peak I \ , Peak I1
`
`11 "C
`
`I
`
`I
`l l 0 C l i J (
`11°C
`
`11 "C
`
`1
`
`20
`
`30
`
`40 20
`
`30
`
`40
`Time (min)
`
`40
`
`so
`
`25
`
`30
`
`35
`
`FIGURE 3
`(a) HPLC analysis of guanylin-(lOl-
`115) 3 at 11,25 and 35 "C; (b) HPLC
`analysis of guanylin-(99-115) 4 at 1 I ,
`25 and 35 "C; (c) HPLC analysis of
`uroguanylin-(89-112) 15 at 11 and
`35 "C; (d) HPLC of peak I (bottom)
`and I1 (top) at 11 "C obtained after
`collection from run (b), peaks were
`separated two times and reanalyzed
`under the same conditions. Gradient:
`1 5 4 5 % buffer B in 60 min.
`
`221
`
`

`

`J. Klodt et al.
`
`detectability of the two isomers by HPLC. Mutations
`or deletions at the N-terminal region of peptides 1, 7,
`9, 12 and 13, and the C-terminal mutation in 12 (Thr
`to Ala) also resulted in two HPLC peaks. In contrast,
`the hybrid mutant 9 appears as a single peak, but con-
`sists of two compounds as detected by two distinct sets
`of NMR resonances (data not shown). Chino et al. (21)
`suspected that the carboxy-terminal leucine residue
`present in uroguanylin-(97-112) (14) may stabilize the
`isomers because the absence of this leucine residue re-
`sulted in a peptide showing a HPLC characteristic simi-
`lar to guanylin. On the other hand, uroguanylin 19 with
`a carboxy-terminal cysteine was homogeneous during
`reverse-phase HPLC. Summarizing the present data, it
`is possible that a C-terminally attached elongation is
`crucial for the stability of topoisomers, but other resi-
`dues, in particular between the inner cysteine residues,
`also influence this phenomenon by their sterical bulk.
`Deduced theoretically by Mao (34), guanylin and
`uroguanylin represent an actual example of topologi-
`cal stereoisomerism. Further studies dealing with the
`sequence dependency of the formation of guanylin
`isoforms and of the influence of variables like pH, sol-
`vent and temperature are currently under investigation
`in our laboratory. Stability and NMR studies of syn-
`thetic uroguanylins 14 and 15 are also in progress.
`
`Biological activity
`Guanylin and uroguanylin peptides had a concentra-
`tion-dependent effect on the intracellular cGMP level
`at concentrations between lo-* and lo4 M, whereas E.
`coli enterotoxin STa was already active at lo-‘ M (Fig.
`4a). Different monocyclic derivatives, isolated as in-
`termediates during synthesis, were biologically inac-
`tive indicating that the two disulfide bonds and,
`therefore, the rigid three-dimensional structure is nec-
`essary for receptor activation. Guanylin lacking
`Thr103, either as a truncated (1) or deletion peptide
`(71, was only effective at a concentration of
`M.
`Thus, Thrl03 is a crucial residue for receptor activa-
`tion. This finding corresponds with earlier reports about
`the ability of rat guanylin to bind to intestinal mem-
`branes (35). Interestingly, amino acid exchange of resi-
`due 102 of guanylin did not influence its activity on
`cCMP generation (Fig. 4a, compounds 12 and 13). Pep-
`tide 6 lacking the endocyclic Glu105 was inactive. Re-
`versing the order of disulfide introduction in human
`guanylin-(99-115) had no effect on HPLC pattern and
`did not influence its bioactivity (4 and 5). From this re-
`sult, it can be concluded that peptides 4 and 5 have a
`similar composition. Compound 8 with the non-
`voluminous residues AGGA between the inner cys-
`teines was inactive, indicating an important role for this
`region in receptor activation. For uroguanylin peptides,
`changes in the N-terminal region, like a specific
`biotinylaminocaproylation (20) or amino acid exchange
`(19) did not influence the increase of cGMP concen-
`
`22%
`
`Pep1,ds
`
`i R l
`
`/‘ --
`/
`/
`
`~
`
`lt1-7M
`
`‘ 1
`
`15
`
`16
`
`17
`PIptldc
`
`18
`
`I(,
`
`21)
`
`yya
`
`c
`
`FIGURE 1
`Effects of synthetic peptides on intracellular cGMP concentration
`of cultured T84 cells. (a) Guanylin-related peptides and (b)
`uroguanylin derivatives (C = control; approxiinately 106 cells/
`well: 50 WLlwell).
`
`tration in T84 cells (Fig. 4b). It is noticeable that dele-
`tion of GlulOl (17) did not influence the bioactivity of
`uroguanylin, whereas deletion of Asp99 resulted in a
`peptide (16) with only minor activity. Superficially, the
`latter effect seems to be similar to guanylin 7 lacking
`residue Thrl03, but the second Asp residue of
`uroguanylin complicates interpretation of a functional
`connection between reduction in bioactivity and the
`amino acid residue 103 in guanylin and residue 99 in
`uroguanylin. An unexpected result was obtained from
`the cGMP bioassay of compound 9. Being a hybrid of
`guanylin and uroguanylin, this compound had only mi-
`nor activity at lo-’ M.
`In the intestinal epithelium, a final effect of GC-C-
`activating peptides is the cGMP-mediated activation of
`the CFTR (cystic fibrosis transmembrane conductance
`regulator) chloride channels, thereby enhancing chlo-
`ride secretion (1,2,5). Selected synthetic peptides were
`tested in their ability to modulate ion transport using
`rat intestinal mucosa mounted in Ussing chambers. As
`shown earlier, the guanylin-induced changes of
`short-circuit current (Isc) can be used as an index of
`
`

`

`chloride secretion (7). The results obtained from
`concentration-dependent effects of synthetic peptides
`on Isc corresponded to those from T84 cell bioassay.
`Figure 5 shows the changes of Isc observed after the
`addition of increasing doses of synthetic peptides.
`Guanylin 3 and uroguanylin 14 were bioactive in con-
`centrations between lo-* and 10“ M. Amino-terminally
`longer guanylin 4 and uroguanylin 15 were slightly
`less bioactive starting at lo-’ M. As in the cGMP as-
`say, [desThrl03Jguanylin-(99-115) (7) had only a mi-
`nor effect at 10 M. These results indicate a connection
`between the peptide structure and GC-C activation and
`chloride secretion.
`
`CONCLUSIONS
`The presented data of the synthesis of guanyliduro-
`guanylin peptides demonstrate a particular necessity to
`use T84 cell bioassay as an additional tool to charac-
`terize the obtained products. Besides disulfide isomers
`with different cysteine connectivity and well-known ra-
`cemization of protected cysteine derivatives during
`solid-phase synthesis (36), the novel form of topologi-
`cal stereoisomerism described may lead to a large and
`confusing number of products having the same mo-
`lecular weight. The formation of topological stere-
`oisomers should be considered in the synthesis of any
`multiple-cysteine peptide. Our results demonstrate that,
`up to now, all published functional studies with bioac-
`tive guanylin reported in the literature have not been
`carried out with a single defined molecule but with a

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket